Cancer Immunotherapy Drug Discovery Outsourcing Market Report, 2025 (Includes Business Impact of COVID-19)

                                          
Abstract, Snapshot, Market Analysis & Market Definition: Global Cancer Immunotherapy Drug Discovery Outsourcing Market


The global Cancer Immunotherapy Drug Discovery Outsourcing market size is projected to reach US$ 1930.5 million by 2026, from US$ 903.01 million in 2020, at a CAGR of 13.5% during 2021-2026.d. Rising awareness regarding advancements in cancer immunotherapy coupled with increasing investments by pharmaceutical companies in outsourcing is projected to bolster the growth of the market. Pharmaceutical companies are focusing on immunotherapies since they are a potential treatment alternative for cancer owing to their ability to reduce the risk of tumor reoccurrence, post chemotherapy.

Expertise in medicine development in specific therapeutic areas and conducting clinical trials across geographies are among the factors supporting the growth of clinical research organizations (CROs). Outsourcing of research activities helps in optimizing funds and time involved in the process. Increasing research and development activities is leading to faster entry of novel leads in the market.

Introduction of advanced therapeutic options such as monoclonal antibodies, cancer vaccines, oncolytic viral therapies, and HDAC inhibitors is anticipated to shape the future of the market. The market being innovation led, competitive rivalry is increasing with rising demand for products with improved efficacy and reduced side effects. Consequently, substantial investments in R & D in cancer immunotherapy is one of the primary strategies of key players in this market.

Furthermore, there is a growing focus on testing therapeutic options such as check point inhibitors, immunomodulators, tumor infiltrating lymphocytes (TILs), and chimeric antigen receptor (CAR) T cell therapies for enhanced efficacy. This, in turn, is stoking the growth of the market.

Market Segmentation, Outlook & Viewpoint: Global Cancer Immunotherapy Drug Discovery Outsourcing Market

Drug Type Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2025)

  
Monoclonal Antibodies
  
Immunomodulators
  
Oncolytic Viral Therapies and Cancer Vaccines
  
Others

Service Type Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2025)

  
Target Identification and Validation
  
Lead Screening and Characterization
  
Cell Based Assays

Cancer Type Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2025)

  
Lung
  
Breast
  
Colorectal
  
Melanoma
  
Prostate
  
Head and Neck
  
Ovarian
  
Pancreatic

Key Players, Recent Developments & Regional Insights: Global Cancer Immunotherapy Drug Discovery Outsourcing Market

The monoclonal antibodies segment was the most prominent medicine type in 2017. Proved efficacy of monoclonal antibodies and introduction of enhanced drug types such as bispecific, naked antigen-binding, and conjugated monoclonal antibodies are attracting attention of pharmaceutical companies.

Cancer vaccines and oncolytic viral therapies are breakthrough innovations in the field of cancer immunotherapy owing to constant R & D efforts of market participants. This immunotherapeutic vaccine includes immune cells of patient converted to dendritic cells by chemical treatment, used against prostate cancer. A few treatment vaccines in the pipeline constitute parts of cells, antigens, and cancer cells.

Therapeutic vaccines have been observed to create anti-cancer antigen acting memory cells in immune system of affected individual. Rising awareness regarding benefits associated with these vaccines has been boosting investments of market players in R & D activities. Therefore, cancer vaccines and oncolytic viral therapies are poised to post the fastest growth over the forecast period.

Growing focus on novel therapeutic options is resulting in advancement of therapeutic options such as CAR T cell therapies, immune checkpoint inhibitors, and tumor infiltrating lymphocytes. These therapies are showing promising results in clinical studies of leU.K.emia and lymphomas. However, side effects associated with these therapies such as extremely high fever and life-threatening low blood pressure issues can impede the growth.

Cancer Insights

Lung cancer accounted for the leading market share in 2017. Late diagnosis of this condition makes chemotherapy inefficient for the treatment of patients. This drawback can be overcome by immunotherapy as it has proved to have remarkable effects on NSCLC (non-small cell lung cancer) conditions. In addition, availability of majority of immunotherapies for NSCLC has been supplementing the growth of the segment.

Ovarian cancer is likely to exhibit the highest CAGR during the forecast period owing to increasing R & D investments and rising prevalence. Immunotherapies have showed positive results in the treatment of ovarian cancer as it enhances patients immune system, in turn, prohibiting the growth of malignant cells. Ovarian oncologys treatment with immunotherapy include checkpoint inhibitors and other adoptive therapies. Ongoing R & D in the field has several upcoming potential drugs for the treatment, which will spur the growth of the segment over the forecast period.

Immunotherapeutic advancements have been noticed in case of several other types such as melanoma, head and neck, and prostate cancer. There are 3 immunotherapeutic drugs in the market for head and neck oncology, one target antibody molecule, cetuximab, and two checkpoint inhibitors, nivolumab and pembrolizumab. Rising prevalence of these cancer types is responsible for encouraging investments in R & D of immunotherapeutic drugs, which in turn is revving up the adoption rate of outsourcing services.

Service Insights

Immunotherapy is one of the most promising oncological therapies with advantages such as fewer side effects, higher efficacy, and increased patient convenience over other treatment solutions. As a result, market players are investing heavily in R & D of immunotherapy-based interventions.

The target identification and validation segment dominated the overall market in 2017. It is projected to remain dominant throughout the forecast period. At present, cancer immunotherapy is in its nascent phase. However, success of currently available immunotherapeutic agents has been drawing attention of most of the big pharmaceutical companies to invest in new drug development. Thus, the market is anticipated to experience an upthrust with the launch of novel drugs, which is estimated to have a positive impact on early drug discovery procedures in the market.

Currently, only a few drugs are commercially available in immuno-oncology. Drug discovery efforts provide a huge scope for generation of novel drugs designed for specific targets. Additionally, trend of outsourcing drug discovery services is rapidly increasing due to factors such as high demand for novel drugs and rising competition among big pharmaceutical companies. Market players are rapidly adopting advanced automation technologies to enhance the quality of services and to reduce turnaround time and operating errors. In addition, automation of the process has significantly reduced the cost of services.

Lead screening procedures are resource and time intensive in nature resulting in demand for developing advanced tools to perform effective assays. These new platforms focus on refining lead selection and optimizing screening procedures with minimal turnaround time. With the introduction of new tools, such as ligand identification and matching software tool, these procedures are progressively becoming less time-consuming and are providing more accurate outputs. Hence, lead screening is expected to emerge as the fastest growing segment during the forecast period.

Regional Insights

North America held the largest revenue share in the market in 2017. Presence of key CROs and big pharmaceutical and biotech companies has been playing a vital in the growth of the regional market. Surging demand for novel drugs in immunotherapy and increasing outsourcing trend of drug discovery processes are estimated to help the region maintain its position in the global arena through 2025.

Several prominent global market players are headquartered in the U.S. These companies are increasing their global presence by setting-up laboratories in Europe and Asia Pacific. These companies have certain advantages such as easy availability of advanced tools used in drug discovery, which enables them to complete discovery process in a shorter time as compared to their competitors. All these factors have been working in favor of the market in North America.

On the other hand, Asia Pacific is expected to witness lucrative growth during the forecast period. Rising number of CROs offering cost efficient drug discovery services is likely to contribute to the growth of the regional market.
In addition, compliance with Good Laboratory Practices (GLP) and increasing use of advanced technology are driving the market in the region. Introduction of novel and advanced immunotherapy drugs in China and Japan and ongoing clinical trials and FDA approvals of new molecular entities are also poised to bode well for the market in the region.

Cancer Immunotherapy Drug Discovery Outsourcing Market Insights

The market is highly competitive in nature. Key players in the market include Covance, Inc.; Explicyte; Aquila BioMedical; Horizon Discovery Group PLC; Crown Bioscience, Inc.; Promega Corporation; HD Biosciences Co., Ltd.; BPS Bioscience, Inc.; Genscript Biotech Corporation; DiscoverX Corporation; Celentyx Ltd.; ImmunXperts SA; Personalis, Inc.; STC Biologics; and Molecular Imaging, Inc.

Pharmaceutical & biotech companies are increasingly collaborating with academic institutions & non-profit organizations to develop new drugs with improved efficacy. Increasing adoption of advanced treatment options for improved healthcare coupled with soaring need for optimum capital utilization has been influencing the competitive rivalry in the global arena.

Key Insights Covered: Global Cancer Immunotherapy Drug Discovery Outsourcing Market

1. North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Cancer Immunotherapy Drug Discovery Outsourcing industry.
2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Cancer Immunotherapy Drug Discovery Outsourcing industry.
3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Cancer Immunotherapy Drug Discovery Outsourcing industry.
4. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Cancer Immunotherapy Drug Discovery Outsourcing industry.
5. Global market size (sales, revenue) forecast by regions and countries from 2019 to 2024 of Cancer Immunotherapy Drug Discovery Outsourcing industry.

Research Methodology: Global Cancer Immunotherapy Drug Discovery Outsourcing Market

  
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
  
Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
  
Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among other